A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs INCAGN 1876 (Primary)
  • Indications Endometrial cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 22 Jun 2016 According to an Agenus Inc. media release, the first patient has been dosed in this trial.
    • 20 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 02 Mar 2016 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top